California-based DNA sequencer Complete Genomicshas announced that China's BGI-Shenzhen has received clearance from the Committee on Foreign Investment in the United States to proceed with buying the company. This purchase, announced on Sept. 15, has been on hold pending approval from the interdepartmental government agency, which includes representatives from the departments of Treasury, Defense, State, Commerce, and Homeland Security.
Shares of Complete Genomics opened 0.6% higher Monday, at $3.15 per share, the same price BGI-Shenzhen bid in September.
The article Acquisition of Complete Genomics by Chinese Company Gets Green Light originally appeared on Fool.com.
Fool contributor Rich Smith has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.